Network pharmacological study on the mechanism of Prunellae Spica in the treatment of Graves’ ophthalmopathy
XIAO Yao1,2 CAO Yewen2 LI Fei1,2 YAN Weitian1 LI Jun1,2 WEI Junping1
1.Department of Endocrinology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China;
2.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China
Abstract：Objective To explore the mechanism of Prunellae Spica in the treatment of Graves’ ophthalmopathy (GO) on the basis of network pharmacology. Methods The main active components and targets of Prunellae Spica were screened by traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) database; the related targets of GO were obtained by GeneCards, OMIM and DisGeNET database; the protein-protein interaction (PPI) network was constructed by using STRING database. The KEGG signal pathway and Gene Ontology bioaccumulation were analyzed by Metascape platform, and molecular docking verification was carried out by using AutoDock Vina software. Results The main active components of Prunellae Spica in the treatment of GO including quercetin, luteolin, kaempferol, and so on. The core targets may be interleukin-6 (IL-6), tumor necrosis factor (TNF), vascular endothelial growth factor A (VEGFA), interleukin-1β; and the core pathways including TNF signal pathway, nuclear factor κB signal pathway and phosphatidylinositol 3 kinase-protein kinase B signal pathway. The results of molecular docking showed that the interaction of quercetin with VEGFA and IL-6 may play a major role in the treatment of GO by Prunellae Spica. Conclusion Prunellae Spica has an impact on immunity and inflammation through multi-components, multi-targets and multi-pathways, and plays an important role in the treatment of GO.
肖瑶1，2 曹晔文2 李菲1，2 晏蔚田1 李俊1，2 魏军平1. 夏枯草治疗Graves眼病作用机制的网络药理学探讨[J]. 中国医药导报, 2021, 18(11): 10-13,19.
XIAO Yao1,2 CAO Yewen2 LI Fei1,2 YAN Weitian1 LI Jun1,2 WEI Junping1. Network pharmacological study on the mechanism of Prunellae Spica in the treatment of Graves’ ophthalmopathy. 中国医药导报, 2021, 18(11): 10-13,19.
[1] 徐蓉娟.内科学[M].2版.北京：中国中医药出版社，2002：273．
[2] 师金娟，冯珍凤，严军.瘿突1号方治疗活动期Ⅲ级Graves眼病疗效观察[J].河南中医，2020，40（9）：1388-1391.
[3] 申雨萍，陆芝兰.陆芝兰运用疏肝清热、软坚散结法治疗Graves眼病经验[J].中国中医眼科杂志，2020，30（1）：49-52.
[4] 俞灵莺，傅晓丹，章晓芳，等.夏枯草干预实验性自身免疫甲状腺炎Th1/Th2失衡的研究[J].中华全科医学，2018， 16（5）：725-728，743.
[5] Zhou MW，Jiang RH，Kim KD，et al. Rosmarinic acid inhibits poly（I：C）-induced inflammatory reaction of epidermal keratinocytes [J]. Life Sci，2016，155：189-194.
[6] 夏枯草口服液临床应用共识专家组.夏枯草口服液治疗甲状腺肿大/结节类甲状腺疾病临床应用专家共识[J].中草药，2020，51（8）：2082-2087.
[7] Hopkins AL. Network pharmacology [J]. Nat Biotechnol，2007，25（10）：1110-1111.
[8] 孟凡翠，汤立达.中药网络药理学研究中存在的问题与发展展望[J].中草药，2020，51（8）：2232-2237.
[9] Ru J，Li P，Wang J，et al. TCMSP：a database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform，2014，6：13.
[10] Szklarczyk D，Gable AL，Lyon D，et al. STRING v11：protein-protein association networks with increased coverage，supporting functional discovery in genome-wide experimental datasets [J]. Nucleic Acids Res，2019，47（D1）：D607-D613.
[11] Zhou YY，Zhou B，Pache L，et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets [J]. Nat Commun，2019，10（1）：1523.
[12] Trott O，Olson AJ. AutoDock Vina：improving the speed and accuracy of docking with a new scoring function，efficient optimization，and multithreading [J]. J Comput Chem，2010，31（2）：455-461.
[13] Yoon JS，Chae MK，Jang SY，et al. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves’ orbitopathy [J]. Invest Ophthalmol Vis Sci，2012，53（9）：5921-5929.
[14] Yoon JS，Lee HJ，Chae MK，et al. Cigarette smoke extract-induced adipogenesis in Graves’ orbital fibroblasts is inhibited by quercetin via reduction in oxidative stress [J]. J Endocrinol，2013，216（2）：145-156.
[15] 夏楠.自身免疫性甲状腺疾病动物模型的建立及抗炎治疗的研究[D].南京：南京大学，2015.
[16] da-Silva WS，Harney JW，Kim BW，et al. The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation [J]. Diabetes，2007，56（3）：767-776.
[17] 唐莉，罗清礼，周晓红，等.Graves眼病患者外周血细胞因子表达的研究[J].中华眼科杂志，2002，38（3）：165-167.
[18] Cawood TJ，Moriarty P，O’Farrelly C，et al. The effects of tumour necrosis factor-alpha and interleukin1 on an in vitro model of thyroid-associated ophthalmopathy；contrasting effects on adipogenesis [J]. Eur J Endocrinol，2006， 155（3）：395-403.
[19] Wang B，Shao X，Song R，et al. The emerging role of epigenetics in autoimmune thyroid diseases [J]. Front Immunol，2017，8：396．
[20] Hick AC，Delmarcelle AS，Bouquet M，et al. Reciprocal epithelial：endothelial paracrine interactions during thyroid development govern follicular organization and C-cells differentiation [J]. Dev Biol，2013，381（1）：227-240.
[21] Liu YH，Chen RH，Wu HH，et al. Association of interleukin-1beta（IL1B）polymorphisms with Graves’ ophthalmopathy in Taiwan Chinese patients [J]. Invest Ophthalmol Vis Sci，2010，51（12）：6238-6246.
[22] 秦贵军，罗方，赵艳艳，等.IL-1β对体外人Graves眼病球后成纤维细胞分泌RANTES的影响[J].郑州大学学报：医学版，2005，40（3）：485-488.
[23] 刘建亭，鲁建华，张文芳.可溶性细胞间黏附分子-1在Graves眼病患者外周血中的表达[J].眼科，2003，12（1）：53-55.
[24] Kurylowicz A，Hiromatsu Y，Jurecka-LB，et al. Association of NFKB1 -94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves’ disease [J]. Genes Immun，2007，8（7）：532-538.
[25] Kumar S，Nadeem S，Stan MN，et al. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves’ ophthalmopathy [J]. J Mol Endocrinol，2011，46（3）：155-163.
京公网安备 11010502046598号